Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Discover a study in which non-selective β-blockers have demonstrated significant potential in preventing decompensation.

Changes like fibrosis, or scarring of the tissue in the liver, may lead to cirrhosis. “Liver inflammation is common and can be related to many causes that are not serious,” says Meaghan M.

liver failure.1 Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: ...

15 Inclusion criteria were age ≥18 years and diagnosis of NAFLD confirmed by liver biopsy. Patients with clinically overt cirrhosis (significant thrombocytopenia, prolonged prothrombin time and/or US ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis ... build up in the liver.